Newsroom

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

January 07, 2025

The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay.

This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies...

MD Anderson’s Lauren Averett Byers receives TAMEST O’Donnell Award for seminal contributions to lung cancer research

BY Clayton Boldt

December 11, 2024

Lauren Averett Byers, M.D., professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center...

MD Anderson and AmMax Bio announce agreements to advance development of AMB-066 in colorectal cancer patients with minimal residual disease

BY Clayton Boldt

December 10, 2024

The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. today announced a worldwide exclusive license agreement and clinical...

MD Anderson statement on BCBS TX ending Medicare Advantage and Medicaid plans

October 29, 2024

Blue Cross Blue Shield notified The University of Texas MD Anderson Cancer Center it will end its Letter of Agreement for Medicare Advantage and Texas Managed Medicaid services, effective Nov. 1, 2024. This does not impact UT System or Texas A&M System retirees on these plans, patients on BCBS commercial or managed care insurance plans, or Medicare patients with a BCBS Medicare Supplemental Plan.

While MD Anderson welcomes...